彩色多普勒超声及Ki-67表达对乳腺癌新辅助化疗疗效评价的应用价值

Role of ultrasonography and Ki-67 expression in evaluation of neoadjuvant chemotherapy for breast cancer

目的探讨彩色多普勒超声与Ki-67在乳腺癌新辅助化疗(NAC)疗效评价中的应用价值。方法利用彩色多普勒超声观察122例NAC前后病灶的超声声像图变化,应用RECIST标准对化疗疗效进行评价,并观察化疗前后Ki-67的变化。结果乳腺癌病灶在化疗前后的大小及内部血流信号变化差异具有显著性(P<0.05)。彩色多普勒超声检查评价NAC疗效的敏感度为89.3%,特异度为53.8%。Ki-67高表达组的NAC的临床有效率高于Ki-67低表达组。结论彩色多普勒超声在NAC疗效评价上具有较高的临床价值,Ki-67表达可预测NAC的疗效。

Objective To analyze the changes of ultrasonography and Ki-67 before and after neoadjuvant chemotherapy for breast cancer,and to assess the value of ultrasonography and Ki-67 in the evaluation of neoadjuvant chemotherapy for breast cancer.Methods The focus changes of 122 cases of breast cancer before and after neoadjuvant chemotherapy were observed by Color Doppler ultrasonography.The therapeutic effect was evaluated by RECIST standard,and the changes of Ki-67 before and after chemotherapy were observed.Results There were significant differences in size and internal blood flow signal of breast cancer before and after chemotherapy（P〈0.05）.The sensitivity of ultrasonography in the evaluation of neoadjuvant chemotherapy for breast cancer was 89.3% and specificity 53.8%.The clinical efficiency of neoadjuvant chemotherapy for breast cancer with high Ki-67 expression was higher than that with low Ki-67 expression.Conclusion Ultrasonography shows high clinical value in the evaluation of neoadjuvant chemotherapy for breast cancer,and the expression of Ki-67 could predict the efficacy of neoadjuvant chemotherapy.